Document Detail


High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial.
MedLine Citation:
PMID:  11075769     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: High-dose cyclophosphamide has been proposed as an alternative immunosuppressive agent for treatment of severe aplastic anaemia, with a response rate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clonal haematological complications. We undertook a phase III, prospective, randomised trial to compare response rates to immunosuppression with either high-dose cyclophosphamide plus cyclosporin or conventional immunosuppression with ATG plus cyclosporin in previously untreated patients. METHODS: Between June, 1997, and March, 2000, 31 patients were enrolled. 15 were assigned cyclophosphamide (1 h intravenous infusion of 50 mg/kg daily for 4 days) and 16 were assigned ATG (40 mg/kg daily for 4 days); both groups received cyclosporin, initially at 12 mg/kg daily with adjustment to maintain concentrations at 200-400 microg/L, for 6 months. The primary endpoint was haematological response (no longer meeting criteria for severe aplastic anaemia). The trial was terminated prematurely after three early deaths in the cyclophosphamide group. Analyses were by intention to treat. FINDINGS: Median follow-up was 21.9 months (range 1-33). There was excess morbidity in the cyclophosphamide group (invasive fungal infections, four cyclophosphamide vs no ATG patients; p=0.043) as well as excess early mortality (three deaths within the first 3 months cyclophosphamide vs no ATG patients; p=0.101). There was no significant difference at 6 months after treatment in the overall response rates among evaluable patients (six of 13 [46%] cyclophosphamide vs nine of 12 [75%] ATG). INTERPRETATION: A longer period of observation will be necessary to assess the secondary endpoints of relapse and late clonal complications as well as disease-free and overall survival. However, cyclophosphamide seems a dangerous choice for treatment of this disorder, given the good results achievable with standard therapy.
Authors:
J F Tisdale; D E Dunn; N Geller; M Plante; O Nunez; C E Dunbar; A J Barrett; T J Walsh; S J Rosenfeld; N S Young
Related Documents :
7803189 - Long-term follow up of patients with common variable immunodeficiency treated with intr...
19240379 - Adherence with long-term asthma management in patients who experienced hospitalized ast...
20581409 - Single maintenance and reliever therapy (smart) of asthma: a critical appraisal.
19711149 - Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a prelim...
8782169 - Sequential treatment of guillain-barré syndrome with extracorporeal elimination and int...
16164159 - Renal involvement in systemic lupus erythematosus in pakistan.
23010989 - Management of acute atrial fibrillation in the emergency department: a systematic revie...
8899269 - Factors influencing graft clarity.
22747529 - A retrospective study of 22 patients with necrotising fasciitis treated at the universi...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Lancet     Volume:  356     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2000-12-01     Completed Date:  2000-12-01     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1554-9     Citation Subset:  AIM; IM    
Affiliation:
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. johntis@intra.niddk.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anemia, Aplastic / drug therapy*,  mortality
Antilymphocyte Serum / administration & dosage,  therapeutic use*
Cyclophosphamide / administration & dosage,  adverse effects*,  therapeutic use
Cyclosporine / administration & dosage,  therapeutic use*
Drug Administration Schedule
Humans
Immunosuppressive Agents / administration & dosage,  adverse effects*,  therapeutic use
Infusions, Intravenous
Middle Aged
Mycoses / etiology
Risk Factors
Chemical
Reg. No./Substance:
0/Antilymphocyte Serum; 0/Immunosuppressive Agents; 50-18-0/Cyclophosphamide; 59865-13-3/Cyclosporine
Comments/Corrections
Comment In:
Lancet. 2001 Apr 7;357(9262):1128-9   [PMID:  11303606 ]
Lancet. 2000 Nov 4;356(9241):1536-7   [PMID:  11075760 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial.
Next Document:  Malaria eradication on islands.